NASDAQ$GYRE
Gyre Therapeutics Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Gyre Therapeutics' financial results for Q3 2024 were announced, with revenue of $25.5 million and a net income of $2.9 million.
Gyre Therapeutics reported a revenue of $25.5 million and a net income of $2.9 million for the third quarter ended September 30, 2024. The company's cash and cash equivalents totaled $15.9 million as of September 30, 2024.
- Gyre's pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC completed with data expected in Q1 2025.
- The company is on track to initiate U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis in 2025.
- Commercial launch of avatrombopag maleate tablets is expected by the first half of 2025.
- Commercial launch of nintedanib is expected in 2025.
Headline financials
Revenue & EPS history
Gyre Therapeutics · Revenue · Quarterly
$25.5M
Revenue by segment
Gyre Therapeutics · $2.3M total across 1 segment · Q3 2021
- License & Collaboration$2.3M—100.0%
Forward guidance
Gyre Therapeutics anticipates several milestones in 2025, including commercial launches and clinical trial initiations.
Tailwinds
- Commercial launch of avatrombopag in the PRC in the first half of 2025.
- Commercial launch of nintedanib in the PRC in 2025.
- Initiation of U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis in 2025.
- Topline data from Phase 3 trial of F351 in CHB-associated liver fibrosis expected in Q1 2025.
- Potential approval of F351 for CHB-associated liver fibrosis in the PRC.
Headwinds
- Decrease in anti-fibrosis drug sales due to fluctuations in the Chinese economy.
- Decrease in generic drug sales due to decreased healthcare spending.
- Increased general and administrative expenses due to costs associated with being a public company.
- Potential delays in clinical trials or regulatory approvals.
- Competition from competing products.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
-0.7%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+8.5%
Avg return
30 days after
49%
23 / 47 earnings
Positive
+11.6%
Q3 2018
Best reaction
-43.2%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +5.8% | +2.8% | -11.2% | |
| Q4 2025 | +2.0% | -10.2% | -5.4% | |
| Q3 2025 | -1.6% | +13.6% | +8.7% | |
| Q1 2025 | +0.5% | +9.6% | -11.3% | |
| Q3 2024 | -13.6% | -21.2% | -39.8% | |
| Q2 2024 | -6.5% | +2.1% | +28.7% | |
| Q1 2024 | -5.5% | +0.5% | -29.3% | |
| Q4 2023 | +8.3% | +8.0% | +0.9% | |
| Q3 2023 | +0.0% | -15.3% | +144.2% | |
| Q2 2023 | +8.8% | +58.8% | +50.0% | |
| Q1 2023 | +5.0% | +5.0% | +5.0% | |
| Q4 2022 | +5.0% | +5.0% | +5.0% | |
| Q3 2022 | -1.8% | +0.0% | -12.5% | |
| Q2 2022 | -1.6% | +3.6% | +2.1% | |
| Q1 2022 | -24.5% | -26.5% | +173.5% | |
| Q4 2021 | +0.0% | -3.0% | -27.3% | |
| Q3 2021 | -43.2% | -51.0% | -62.9% | |
| Q2 2021 | +7.4% | +3.7% | +10.3% | |
| Q1 2021 | -2.4% | -5.4% | -9.5% | |
| Q3 2020 | +4.5% | +7.4% | +11.3% | |
| Q2 2020 | -0.6% | -2.0% | -13.5% | |
| Q1 2020 | +7.2% | -2.7% | +21.9% | |
| Q3 2019 | -3.1% | -6.1% | -8.7% | |
| Q2 2019 | +6.7% | -3.2% | -22.1% | |
| Q1 2019 | -5.3% | +2.7% | -9.2% | |
| Q3 2018 | +11.6% | +24.7% | +20.0% | |
| Q2 2018 | +6.6% | +6.6% | +11.9% | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | +2.3% | — | — | |
| Q3 2014 | +1.2% | — | — | |
| Q2 2014 | -0.4% | — | — | |
| Q1 2014 | +3.7% | — | — | |
| Q4 2013 | -0.8% | — | — | |
| Q3 2013 | -5.4% | — | — | |
| Q2 2013 | -3.6% | — | — | |
| Q1 2013 | +0.5% | — | — | |
| Q4 2012 | -0.5% | — | — | |
| Q3 2012 | +0.7% | — | — | |
| Q2 2012 | -0.9% | — | — | |
| Q1 2011 | -2.7% | — | — | |
| Q1 2012 | +0.4% | — | — | |
| Q4 2011 | +0.1% | — | — | |
| Q4 2009 | +0.1% | — | — | |
| Q3 2010 | +3.9% | — | — | |
| Q3 2011 | +3.9% | — | — | |
| Q2 2010 | -1.4% | — | — | |
| Q2 2011 | -1.4% | — | — | |
| Q4 2010 | -1.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro